Chordia Therapeutics: Abstracts relating to the Phase 1 clinical trial of the CLK inhibitor CTX-712 were selected at the 86th Annual Meeting of the Japanese Society of Hematology

JPX · Oct 1 07:59

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.